Objectives: We studied patients managed by active surveillance to determine whether there was a difference over time in apparent diffusion coefficients (ADCs) derived from diffusion-weighted MRI in those who progressed to radical treatment (progressors, n517) compared with those who did not (non-progressors, n533). Methods: 50 consecutive patients (Stage T1/2a, Gleason grade # 3+4, prostate-specific antigen (PSA) ,15 ng ml -1 , ,50% cores positive) were imaged endorectally (baseline and 1-3 years follow-up) with T 2 weighted (T 2 W) and echo-planar diffusion-weighted MRI sequences. Regions of interest drawn on ADC maps with reference to the T 2 W images yielded ADC all (b50-800), ADC fast (b50-300) and ADC slow (b5300-800) for whole prostate (minus tumour) and tumour (low signal-intensity peripheral zone lesion in biopsy-positive octant). Results: Tumour and whole prostate ADC all and ADC fast were significantly reduced over time in progressors (p50.03 and 0.03 for tumours, respectively; p50.02 and 0.007 for the whole prostate, respectively). There were no significant changes in ADC over time in non-progressors. A 10% reduction in tumour ADC all indicated progression with a 93% sensitivity and 40% specificity (A z of receiver operating characteristic (ROC) curve 5 0.68). Percentage reductions in whole prostate ADC all , ADC fast and ADC slow were also significantly greater in progressors than in non-progressors (p50.01, 0.03 and 0.008, respectively).Conclusion: This pilot study shows that DW-MRI has potential for monitoring patients with early prostate cancer who opt for active surveillance.